These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 19210298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Jun 15; 29(12):1261-72. PubMed ID: 19392864
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC.
    Clin Gastroenterol Hepatol; 2012 Mar 15; 10(3):247-53. PubMed ID: 22155561
    [Abstract] [Full Text] [Related]

  • 6. Dexlansoprazole MR: a review.
    Hershcovici T, Jha LK, Fass R.
    Ann Med; 2011 Aug 15; 43(5):366-74. PubMed ID: 21366513
    [Abstract] [Full Text] [Related]

  • 7. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR, Marzella N.
    Clin Ther; 2010 Aug 15; 32(9):1578-96. PubMed ID: 20974316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C, Desilets AR, Willett K.
    Ann Pharmacother; 2010 May 15; 44(5):871-7. PubMed ID: 20371754
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, Damico D, Hamelin B.
    Am J Gastroenterol; 2001 Jan 15; 96(1):27-34. PubMed ID: 11197282
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D, Gold BD, Pilmer B, Hunt B, Korczowski B, Perez MC.
    Dig Dis Sci; 2019 Feb 15; 64(2):493-502. PubMed ID: 30390234
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M, Wu J, Perez MC.
    J Pediatr Gastroenterol Nutr; 2012 Jan 15; 54(1):41-7. PubMed ID: 21716130
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
    Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL.
    Am J Gastroenterol; 2001 Nov 15; 96(11):3089-98. PubMed ID: 11721754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.